Key Laboratory of Pulp and Paper Science & Technology of Ministry of Education, State Key Laboratory of Biobased Material and Green Papermaking, Faculty of Light Industry, Qi Lu University of Technology (Shandong Academy of Sciences), Jinan 250353, PR China.
Key Laboratory of Pulp and Paper Science & Technology of Ministry of Education, State Key Laboratory of Biobased Material and Green Papermaking, Faculty of Light Industry, Qi Lu University of Technology (Shandong Academy of Sciences), Jinan 250353, PR China.
Key Laboratory of Pulp and Paper Science & Technology of Ministry of Education, State Key Laboratory of Biobased Material and Green Papermaking, Faculty of Light Industry, Qi Lu University of Technology (Shandong Academy of Sciences), Jinan 250353, PR China.
Key Laboratory of Pulp and Paper Science & Technology of Ministry of Education, State Key Laboratory of Biobased Material and Green Papermaking, Faculty of Light Industry, Qi Lu University of Technology (Shandong Academy of Sciences), Jinan 250353, PR China.
Key Laboratory of Pulp and Paper Science & Technology of Ministry of Education, State Key Laboratory of Biobased Material and Green Papermaking, Faculty of Light Industry, Qi Lu University of Technology (Shandong Academy of Sciences), Jinan 250353, PR China. Electronic address: wjy@qlu.edu.cn.
Institute of Optical Materials and Chemical Biology, Guangxi Key Laboratory of Electrochemical Energy Materials, School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, China.
Institute of Optical Materials and Chemical Biology, Guangxi Key Laboratory of Electrochemical Energy Materials, School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, China.
Institute of Optical Materials and Chemical Biology, Guangxi Key Laboratory of Electrochemical Energy Materials, School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, China.
Second-generation direct-acting antivirals (DAAs) have shown high efficacy in the treatment of chronic hepatitis C virus (HCV) infections in clinical trials. This study aimed to estimate the effective...
In this observational cohort study, patients with active HCV infection who commenced DAA treatment between 2015 and 2020 in Navarre, Spain, were studied. Sustained virological response (SVR), defined ...
Of a total 1366 HCV-infected patients that commenced treatment, 19.3% (n = 263) were HIV-coinfected. After the first DAA treatment, SVR was achieved in 96.6% (n = 1320/1366) of patients and in 97.7% (...
With DAAs, SVR was achieved in all patients with active HCV infection who completed follow-up, and a second course of treatment was only necessary in a small proportion of patients. Adherence to treat...
It is possible that adult ED patients consider their hepatitis C virus (HCV) risk factor history when deciding whether to accept HCV screening. To help address this question, we examined whether self-...
This study was conducted among adult patients ≥18 years old participating in a universal, ED-based HCV screening programme in New York City between 22 January 2019 and 9 April 2020. Participants were ...
Of the 4658 ED patients surveyed, 2846 (61%) accepted and 1812 (39%) declined HCV screening. Among these participants, 38% reported at least one HCV risk factor, most commonly injection drug use. Self...
HCV risk factors were self-reported by more than one-third of ED patients but were not more commonly present among those who accepted HCV screening....
Hepatitis B and hepatitis C are a global burden and underscore the impact of preventable acute and chronic diseases on personal as well as population level health. Caring for pediatric patients with h...
The war invasion of Ukraine in February 2022 led to mass migration. By January 3, 2023, nearly a million people sought refuge in Poland. The Polish Act on Assistance to Ukrainian Citizens provided com...
This paper aims to summarize the epidemiological situation of HCV infections in Poland in 2022, a year characterized by dual crises....
Epidemiological surveillance case-based data on HCV for 2022, diagnosis rates from bulletins for the years 2014-2022, and the number of deaths for 2022 from Statistics Poland were compared with previo...
In 2022, the rate of new HCV diagnoses rose to 6.68 per 100,000, totaling 2,528 cases (a 46% increase from the previous year). Polish nationals accounted for 87% of cases. Gender distribution was equa...
Expanding the availability and accessibility of testing is essential, particularly addressing the needs of key populations, including non-Polish speakers. The strategy for HCV elimination should encom...
It is unknown whether hepatitis C virus (HCV)-cured people with HIV (PWH) without cirrhosis reached the same mortality risk as HCV-uninfected PWH. We aimed to compare mortality in PWH cured of HCV by ...
Nationwide hospital cohort....
HIV-controlled participants without cirrhosis and HCV-cured by DAAs started between September 2013 and September 2020, were matched on age (±5 years), sex, HIV transmission group, AIDS status, and bod...
The analysis included 3961 HCV-cured PWH (G1) and 33 872 HCV-uninfected PWH (G2). Median follow-up was 3.7 years in G1 [interquartile range (IQR): 2.0-4.6], and 3.3 years (IQR: 1.7-4.4) in G2. Median ...
Despite HCV cure and HIV viral suppression, after controlling on factors related to mortality, DAA-cured PWH without cirrhosis remain at higher risk of all-cause mortality than people with HIV monoinf...
High costs of direct-acting antivirals (DAAs) have led to their restricted access for patients with hepatitis C virus (HCV)....
The aim was to assess how HCV treatment access and predictors of HCV treatment changed in the post-DAA period compared with pre-DAA period....
A retrospective cohort study using Arizona Medicaid data was conducted for patients with HCV to compare treatment initiation rates between pre-DAA (January 2008-October 2013) and post-DAA (November 20...
Twenty-four thousand and ninety and 28,756 patients during the pre-DAA and post-DAA periods were identified. Overall, 12.6% were treated in the post-DAA period compared with 7.8% in the pre-DAA period...
Although treatment initiation increased and disparities for Black beneficiaries compared with White beneficiaries attenuated in the post-DAA period, only 13% of Arizona Medicaid patients with HCV rece...
Although anti-hepatitis C virus (HCV) assay is widely used to screen for HCV infection, it has a high false-positive (FP) rate in low-risk populations. We investigated the accuracy of anti-HCV signal-...
We retrospectively analyzed 77,571 patients with anti-HCV results. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic accuracy of anti-HCV S/CO ratio in ...
Overall, 1,126 patients tested anti-HCV positive; 34.7% of patients were FP based on HCV RNA and/or recombinant immunoblot assay (RIBA) results. The age and sex-adjusted anti-HCV prevalence was 1.22%....
The anti-HCV S/CO ratio is highly accurate for discriminating TP from FP HCV infection and should be considered when diagnosing HCV infections....
Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to...
We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were ...
Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: "being 'worthy' of the cure", "spatially enacted st...
Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-...
The country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and ...
The serosurvey used a stratified, multistage cluster design with systematic sampling to include adults and children (aged 5-17 years) providing consent (or assent with parental consent). Blood samples...
Overall, 7237 adults and 1473 children were surveyed. Among adults, the prevalence of anti-HCV was 6.8% (95% CI, 5.9-7.7). The HCV RNA prevalence was 1.8% (95% CI, 1.3-2.4), representing a 67% reducti...
These results demonstrate substantial progress made in Georgia since 2015. These findings can inform strategies to meet HCV elimination targets....
There are limited data regarding heart transplantation in the setting of hepatitis C virus (HCV) infection in either recipients or donors, as the practice was infrequent, given concerns of worse post-...
